CUSTOM DERMATOLOGY SEARCH:
The Management of Chronic Pruritus in the Elderly
Tejesh Patel, MD1 and Gil Yosipovitch, MD2,3
Pruritus is the most common skin complaint in patients over the age of 65 years.1,2 This often neglected symptom can have a profound impact on the quality of life in the elderly, especially through sleep deprivation. Given the multitude of variables that come with advanced age, the management of pruritus in the elderly poses a particular clinical challenge.
Pruritus in advanced age may result from a variety of etiologies. Xerosis (dry skin), which increases with age, is probably the most common cause of pruritus in the elderly.3,4 As skin ages, the integumentary and vascular systems undergo atrophy, leading to suboptimal moisture retention. However, many elderly patients have pruritic skin without xerosis. Other skin changes in advanced aged patients that may contribute to itch include decreased skin surface lipids and clearance of transepidermally absorbed materials from the dermis, reduced sweat and sebum production, as well as diminished barrier repair.4
A detailed history, review of systems, and physical examination are of prime importance in guiding antipruritic treatment of senescent skin. Once cutaneous and systemic causes of itch are excluded, idiopathic itch of the elderly may be considered. However, if an underlying cause is discovered, it should be addressed, as this frequently leads to symptomatic improvement. Certain pruritic cutaneous diseases are more prevalent in the elderly population, such as xerosis, nummular dermatitis, and seborrheic dermatitis. The later is especially common in patients with dementia and Parkinson’s disease. Systemic diseases that are associated with pruritus, such as chronic kidney disease, hepatic dysfunction, and endocrine disorders, are also more prevalent in the elderly. Notably, infectious etiologies of pruritus, including scabies and lice, may be more common in this age group especially within institutionalized care settings. In addition, medications frequently used in the elderly increase the possibility of drug-induced pruritus (e.g., aspirin, opioids, and angiotensin converting enzyme inhibitors). Another serious consideration in this cohort is that chronic pruritus may be a presenting sign of underlying malignancy (e.g., low grade lymphoma, multiple myeloma, and myleodysplastic syndromes), and thus, any case with a high index of suspicion necessitates a thorough work-up.5 Psychogenic and neuropathic disorders are also common causes in this age group.6
The management of pruritus in the elderly poses a particular challenge. Physical and cognitive impairments may make application of topical treatments impossible and compliance an issue. Comorbid conditions, especially those involving the liver and kidney, as well as the frequent polypharmacy in this age group, confers a greater risk of adverse drug reactions. At present, there is no universally accepted therapy for itch. Instead, management of pruritus, especially in the elderly, requires an individualistically tailored approach with consideration of the patient’s general health, the severity of symptoms, and the adverse effects of available treatments. Some of the treatments discussed are unlicensed for use in pruritus and should be administered under a specialist setting.
Moisturizers, Emollients and Barrier Creams
Moisturizers, emollients, and barrier repair creams are the mainstay of pruritus treatment in the elderly, especially in cases associated with xerosis. These nonpharmacologic compounds reduce pruritus through improving barrier function by helping to prevent transepidermal water loss and possibly preventing the entry of irritants and other itch-causing agents. Topical therapies with a low pH may be especially useful in optimizing the skin barrier function through their maintenance of the normal acidic pH of the skin surface. In addition, low pH topical therapies may be of further benefit through their reduction in the activity of serine proteases, such as mast cell tryptase, which is known to activate protease-activating receptor 2 (PAR2) on skin nerve fibers. This notion stems from recent studies suggesting serine proteases, via PAR2 located on C fiber terminals, may play an important role in mediating pruritus.8,9
Topical corticosteroids do not directly exert antipruritic effects, instead their therapeutic benefits are derived from their anti-inflammatory properties. Therefore, they should only be used to provide relief of itching that is associated with inflammatory skin diseases, such as nummular dermatitis or psoriasis. Topical corticosteroids should not be used to treat generalized chronic itch or for prolonged periods. Of note, the elderly are particularly vulnerable to the adverse effects (especially skin thinning) from the excessive use of topical corticosteroids.10
The topical calcineurin inhibitors, tacrolimus and pimecrolimus, have been shown to be effective in reducing pruritus in conditions such as chronic irritant hand dermatitis, seborrheic dermatitis, graft-versus-host disease, lichen sclerosis, anogenital pruritus, and prurigo nodularis.11 The antipruritic effects of topical calcineurin inhibitors may be mediated via TRPV1, a member of the transient receptor potential (TRP) family of excitatory ion channels, located on nerve fibers. Although the recognized side-effects of these agents include transient burning and stinging sensations, they are particularly useful in the elderly as there is no associated risk of skin atrophy.
Menthol, a naturally occurring cyclic terpene alcohol of plant origin, is frequently used as a topical antipruritic at concentrations of 1-3%. It has been shown that menthol elicits the same cooling sensation as low temperature through the TRPM8 receptor.12 Both cooling the skin and menthol use result in the relief of experimentally induced itch, although the latter is not associated with a decrease in skin temperature. Of note, elderly patients who report a reduction in pruritus with cooling may especially benefit from topical therapies containing menthol.12
Capsaicin has been reported to have a beneficial effect in chronic, localized pruritic disorders, particularly those of neuropathic origin, which are common in the elderly (e.g., postherpetic neuralgia, notalgia paresthetica, and brachioradial pruritus).13,14 The TRPV1 receptor has recently been implicated in the pathogenesis of pruritus and may be the target through which capsaicin exerts its antipruritic effect.15 A recognized side-effect is an initial intense transient burning sensation at the application site, which may lead to poor compliance, particularly in the elderly.
Pramoxine, a local anesthetic, reduces itch by interfering with transmission of impulses along sensory nerve fibers and has been shown to reduce pruritus in adult hemodialysis patients in a double-blinded study.16 Polidocanol is a non-ionicsurfactant with both local anesthetic properties and moisturizing effects. A combination of 5% urea and 3% polidocanol was found to significantly reduce pruritus in patients with atopic dermatitis, contact dermatitis, and psoriasis.17
Topical Salicylic Acid
Topical salicylic acid, a cyclooxygenase inhibitor, has been shown to significantly reduce pruritus in patients with lichen simplex chronicus, possibly due to their inhibitory effects on prostanoids.18,19 Of note, oral salicylates do not relieve pruritus except in polycythemia vera.
N-palmitoylethanolamine, a cannabinoid receptor CB2 agonist, has been incorporated into creams and shown to reduce pruritus reported in patients with atopic dermatitis, lichen simplex, prurigo nodularis, and chronic kidney disease-associated itching.20-22
With the exception of chronic urticaria, antihistamines have little effect on conditions associated with pruritus. Sedating (first generation) antihistamines may have a role via their soporific effects on nocturnal pruritus, but in the elderly caution must be taken to avoid causing excessive drowsiness.23
The serotonin-norepinephrine re-uptake inhibitor (SNRI), mirtazapine, has been reported to relieve itch in patients with advanced cancers (e.g., leukemia and lymphoma, including cutaneous lymphoma), chronic kidney disease, and cholestasis.24-26 Mirtazapine may also be especially useful for the treatment of nocturnal pruritus.25 Additionally, selective serotonin re-uptake inhibitors (SSRIs) may have antipruritic effects. The SSRIs, paroxetine and fluvoxamine, have been shown to reduce chronic pruritus, with the most favorable responses seen in patients with pruritus due to atopic dermatitis, systemic lymphoma, and solid carcinoma; whilst sertraline has been shown to be an effective treatment for pruritus associated with chronic liver disease.27,28
Opioid Agonists and Antagonists
An imbalance of the endogenous opioidergic system may have a role to play in the pathophysiology of pruritus. Itch is induced by both μ-opioid receptor agonists and κ-opioid receptor antagonists, while μ-receptor antagonists and κ-receptor agonists can reduce it. Studies have shown the antipuritic effects of μ-opioid receptor antagonists, such as naltrexone (in patients with cholestasis, end-stage renal disease, burns, and atopic dermatitis) and nalmefene (in patients with cholestasis, atopic dermatitis, and urticaria).30-34
The κ-opioid receptor agonists, butorphanol and nalfurafine, appear to have an antipruritic effect in patients with chronic intractable itch and chronic kidney disease, respectively.35,36 Due to the potential adverse effects associated with opioid agonists and antagonist, treatment is advisable under specialist supervision and at lower initial doses, especially in the elderly.
The neuroleptics, gabapentin and pregablin, are structural analogs of the neurotransmitter γ-aminobutyric acid (GABA). The exact mechanisms of their antipruritic effects are not clear, but they may be related to inhibition of central itch pathways. Neuroleptics may be particularly useful in the elderly for neuropathic pruritus related to conditions such as brachioradial pruritus, postherpetic neuralgia, and notalgia paresthetica.6,14 Gabapentin has been shown to reduce pruritus in patients with chronic kidney disease and lymphoma, but treatment can actually worsen the itching in patients with cholestasis.26,37 Of note, it has been suggested that using a lower dose of gabapentin with slow upward titration may reduce the risk of gabapentin-induced neurotoxicity and/or coma in patients with reduced renal function, a problem that may be more prevalent in the elderly.38 Additionally, treatment with pregabalin should not be stopped abruptly due to the risk of withdrawal symptoms.39
Ultraviolet A (UVA), broadband ultraviolet B (BB-UVB), and narrowband UVB (NB-UVB)-based phototherapies have been used for over three decades to treat various pruritic dermatoses. This mode of treatment may be particularly suitable in the elderly as it avoids the risk of adverse drug reactions (although the risk of phototoxicity is increased) and overcomes challenges such as physical and cognitive limitations that can lead to noncompliance.
The multitude of variables that come with advanced age means that the management of pruritus in the elderly continues to pose a particular diagnostic and therapeutic challenge. Physical and cognitive limitations, multiple comorbid conditions, and polypharmacy are some aspects that can influence choice of treatment in this age group. Management of pruritus in the elderly must take an individualistically tailored approach with consideration of the patient’s general health, the severity of symptoms, and the adverse effects of treatment.
In this issue:
All content ©2004-2014 SkinTherapyLetter® |
Last modified: Tuesday, 15-Dec-2015 15:40:14 MST